pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Carvykti
drug
save

ciltacabtagene autoleucel

Marketedupdated 7mo ago
by Janssen Biotech Inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ciltacabtagene autoleucel

  • phase2CAR- PRISM (PRecision Intervention Smoldering Myeloma)active not recruitingn=20

News(10)

  • Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
    The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
    biopharma_dive · 2d ago
  • China has a clear shot to 2030 goals, though economic, cultural barriers remain
    To grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.
    biospace · 10d ago
  • Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
    The BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibilit…
    biospace · 14d ago
  • 6 potential blockbusters that could pave China’s path to 2030 ambitions
    In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…
    biospace · 17d ago
  • Most new drugs are still too costly at launch, ICER says
    A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
    biopharma_dive · 1mo ago
  • Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
    Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
    endpoints · 1mo ago
  • J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
    Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
    biospace · 1mo ago
  • Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves
    → Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act. The company’s shares {$LEGN} are down 50% ...
    endpoints · 2mo ago
  • Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
    After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
    fiercebiotech · 2mo ago
  • Unlocking cell surface protein research with site-specific labeling
    Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
    biospace · 2mo ago
view all news mentions →
brand
Carvykti
generic
ciltacabtagene autoleucel
indication
Refractory Multiple Myeloma
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?